Search articles by title, topic or section.
Khabre desk
Recent reporting, analysis and explainers from the glioblastoma desk.
health
A single-site phase 1 trial evaluated D2C7-ATC, an EGFR-targeted antibody-toxin conjugate, in recurrent malignant glioma. Among 72 patients with IDH-wild-type recurrent glioblastoma, median overall survival was 7.9 months.
health
A prospective six-patient preprint evaluated Hiporfin for fluorescence-guided surgery and cavity photodynamic therapy in recurrent glioblastoma. Fluorescence had moderate specimen-level diagnostic accuracy, with some tumour samples not fluorescing.
health
A medRxiv preprint analysing preoperative imaging from 999 people with newly diagnosed glioblastoma found that a tractography-based measure of tumour involvement across white-matter pathways was more consistently associated with overall survival than tumour volume. The finding is based on a multi-institution imaging and survival analysis, not a treatment trial.